Mifeprex Post-Marketing Restriction Compliance To Be Questioned By Rep. Souder
This article was originally published in The Pink Sheet Daily
Executive Summary
Danco Labs declined to testify at a hearing on deaths associated with the use of the abortifacient mifepristone.
You may also be interested in...
Corcept’s Second Corlux Phase III Trial Enrolled For Psychotic Major Depression
Company expects data from three Phase III trials of mifepristone for PMD by year-end.
Corcept’s Second Corlux Phase III Trial Enrolled For Psychotic Major Depression
Company expects data from three Phase III trials of mifepristone for PMD by year-end.
GOP Lawmakers Seize On Adverse Event Analysis, Push For Mifeprex Withdrawal
Rep. Bartlett (R-Md.) is seeking to revitalize support for the “RU-486 Suspension & Review Act.”